Lupin has informed that it enclosed a Press Release titled ‘Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.’
The above information is a part of company’s filings submitted to BSE.